1519 studies found for:    "Sexually Transmitted Diseases, Viral"
Show Display Options
Rank Status Study
1 Completed Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Lentivirus Infections;   Retroviridae Infections;   RNA Virus Infections;   Virus Diseases;   Sexually Transmitted Diseases, Viral;   Sexually Transmitted Diseases;   Immunologic Deficiency Syndromes;   Immune System Diseases;   Slow Virus Diseases
Interventions: Procedure: Circumcision;   Procedure: Flexible sigmoidoscopy
2 Completed Measuring Responses to Sublingual Antigens
Condition: Sexually Transmitted Diseases, Viral
Intervention: Biological: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
3 Completed Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse
Conditions: Alcoholism;   Child Abuse, Sexual;   Sexual Abuse;   Sexual Behavior;   Sexually Transmitted Diseases, Viral
Intervention: Behavioral: Trauma-focused group therapy
4 Completed HIV Prevention Intervention for Couples
Condition: Acquired Immunodeficiency Syndrome
Interventions: Behavioral: Couples HIV counseling and testing;   Behavioral: Women's relationship-focused HIV counseling and testing
5 Recruiting Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
Condition: Acute HIV Infection
Interventions: Drug: cART(TDF/AZT+3TC+LPV/r);   Procedure: CTL infusion
6 Completed Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Condition: HIV Infection
Intervention: Drug: Panobinostat
7 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
8 Terminated A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR);   Drug: 3-4 commercially available antiretroviral drugs
9 Recruiting Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine
Condition: Acquired Immunodeficiency Syndrome
Interventions: Biological: Ad5-gag;   Biological: Placebo
10 Completed Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
Condition: Hepatitis C, Chronic
Interventions: Drug: Peg-Interferon Alpha-2A;   Drug: Ribavirin
11 Not yet recruiting Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Condition: Genital Warts
Interventions: Biological: Quadrivalent HPV vaccine;   Biological: Hepatitis B vaccine
12 Recruiting Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis
Conditions: Acute HIV Infection;   HIV CNS Involvement
Interventions: Drug: TDF/3TC/EFV + Telmisartan;   Drug: TDF/3TC/EFV only
13 Not yet recruiting Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
Condition: HIV Infection
Interventions: Other: ART initiation at time of HIV diagnosis;   Other: ART at 24 weeks post-diagnosis
14 Not yet recruiting Liraglutide for HIV-associated Neurocognitive Disorder
Conditions: HIV Infection;   Diabetes Mellitus Type 2;   Obesity;   Overweight;   Metabolic Syndrome
Intervention: Drug: Liraglutide
15 Not yet recruiting Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: RPV;   Drug: DTG/RPV FDC
16 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
17 Not yet recruiting Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg tablet;   Drug: Lamivudine 300 mg tablet;   Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA);   Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
18 Recruiting A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Intervention: Drug: ABT-493/ABT-530
19 Completed Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
Condition: HIV Infections
Interventions: Drug: Enfuvirtide;   Drug: Optimized background antiretroviral regimen (OB)
20 Completed MMR Vaccination Among HIV-infected Adults
Condition: HIV
Intervention: Biological: 0.5 ml of MMR vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years